Investment Rating - The industry maintains a "Recommended" rating, with a focus on new consumption sectors such as beauty care, IP derivatives, and gold jewelry [5][35]. Core Insights - The total retail sales of consumer goods in China for the first half of 2025 reached 24.55 trillion yuan, showing a year-on-year increase of 5%. In June, the retail sales totaled 4.23 trillion yuan, growing by 4.8% year-on-year, which was below the expected 8.4% due to the timing of the Dragon Boat Festival and the pre-release of demand during the 618 shopping festival [3][23]. - The beauty care sector is highlighted with significant developments, including the strategic expansion of Ai Er Bo Shi in Southeast Asia and the announcement of a new CEO at Kenvue [27][3]. - Bubble Mart is expected to see a revenue increase of no less than 200% and a profit increase of no less than 350% for the first half of 2025 [32][5]. Summary by Sections Market Performance - From July 14 to July 18, 2025, the trade retail, social services, and beauty care sectors experienced changes of +0.23%, +1.05%, and -0.14% respectively, ranking 18th, 13th, and 22nd among 31 primary industries [14][16]. Key Industry Data and News - In June 2025, the retail sales of consumer goods grew by 4.8%, with a total of 21.8 trillion yuan in goods retail sales for the first half of the year, reflecting a 5.1% year-on-year increase [23][22]. - The airline industry saw an increase in passenger flights, with nearly 118,000 flights executed nationwide in the 28th week of 2025, marking a 3.2% year-on-year rise [4][27]. Company Announcements - Bubble Mart's half-year performance forecast indicates a revenue growth of at least 200% and a profit increase of at least 350% [32][5]. - Other companies like Rongzi Co. and Longzi Co. also reported significant profit forecasts, with Rongzi expecting a profit increase of 31.74% to 55.69% [34][33]. Investment Recommendations - The report recommends focusing on companies such as Shangmei Co., Juzi Bio, Marumi Bio, and others within the beauty care and new consumption sectors [5][35].

Core Viewpoint - The AI Fund Minsheng Jianyin Dividend Return Mixed Fund (690009) reported a profit of 2.2766 million yuan for Q2 2025, with a net asset value growth rate of 4.33% during the period [3] Fund Performance - As of the end of Q2 2025, the fund's scale was 54.2078 million yuan [15] - The fund's weighted average profit per share for the period was 0.1049 yuan [3] - The fund's unit net value as of July 21 was 2.505 yuan [3] - The fund's one-year cumulative net value growth rate was 6.05%, ranking 732 out of 880 comparable funds [3] - The fund's three-month net value growth rate was 4.02%, ranking 757 out of 880 comparable funds [3] - The fund's six-month net value growth rate was 5.25%, ranking 598 out of 880 comparable funds [3] - The fund's three-year net value growth rate was -23.05%, ranking 672 out of 871 comparable funds [3] Investment Strategy - The fund manager, Deng Kaicheng, maintains a positive outlook on value style and dividends, focusing on stable investments while seeking flexible dividend opportunities [3] - The fund continues to allocate a significant portion to the financial sector and actively seeks companies with improved operations and higher dividend payouts [3] Risk Metrics - The fund's three-year Sharpe ratio was -0.3336, ranking 749 out of 875 comparable funds [8] - The maximum drawdown over the past three years was 33.6%, ranking 513 out of 873 comparable funds [10] - The maximum drawdown in a single quarter occurred in Q1 2021, reaching 18.96% [10] Portfolio Composition - The average stock position over the past three years was 74.32%, compared to the industry average of 80.43% [13] - The fund reached its highest stock position of 77.33% at the end of H1 2024, with a lowest position of 35.27% at the end of Q1 2019 [13] - As of Q2 2025, the fund's top ten holdings included companies such as Chao Hong Ji, Zhong Chong Co., Runben Co., and Meidi Group [17]

Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry, highlighting innovative business models driving growth in the light medical beauty sector, particularly recommending attention to the company "Xinyang" [2][9]. Core Insights - The cosmetics and medical beauty sector has underperformed the market recently, with the Shenwan Beauty Care Index declining by 0.1% from July 11 to July 18, 2025, while the Shenwan Cosmetics Index fell by 0.9%, underperforming the Shenwan A Index by 2.3 percentage points [3][4]. - Innovative business models are driving growth in light medical beauty, contrasting with traditional medical beauty institutions facing stagnation due to high costs and weak consumer demand. Xinyang's high cost-performance ratio, chain operations, and app-based customer conversion model are seen as new growth drivers for the sector [9][10]. - The report emphasizes the importance of supply-side innovations in stimulating consumer demand and driving industry recovery, despite short-term macroeconomic challenges [9]. Summary by Sections Industry Performance - The cosmetics and medical beauty sector has shown weak performance compared to the market, with specific indices reflecting declines during the reporting period [3][4]. - The top-performing stocks in the sector included Zhongshun Jierou (+10.8%) and Juzibio (+6.1%), while the worst performers were Shangmei Shares (-11.1%) and Baiya Shares (-4.3%) [5]. Key Company Insights - Linqingxuan, a high-end domestic skincare brand, has seen revenue growth from 690 million yuan in 2022 to 1.21 billion yuan in 2024, with net profit turning from a loss of 6 million yuan to a profit of 187 million yuan [10][15]. - The company has established a strong product matrix and supply chain advantages, with production capacity reaching 40 million units annually [16][17]. - The report also highlights the growth of the "Plant Doctor" brand, which has achieved a net profit CAGR of 24% from 2022 to 2024, supported by a robust channel network and operational efficiencies [10][12]. Market Trends - The report notes a shift in the cosmetics market from quantity to quality, with a significant increase in e-commerce sales, which accounted for 47% of total cosmetics sales in 2024, up from 22% in 2016 [11]. - The domestic market is witnessing a rise in local brands, with a notable increase in market share for domestic products, reflecting changing consumer preferences and the impact of the "national tide" [11][28]. Financial Performance - The report indicates that the overall retail sales of cosmetics in China reached 229.1 billion yuan in the first half of 2025, with a year-on-year growth of 2.9%, although June saw a decline of 2.3% due to promotional timing [21][24]. - The performance of major companies like Meili Tianyuan is highlighted, with projected revenue of at least 1.45 billion yuan for the first half of 2025, representing a growth of at least 27% [24].

Investment Rating - The report maintains a positive outlook on the cosmetics and medical beauty industry, indicating a "Buy" recommendation for several companies within the sector [2][14]. Core Insights - The cosmetics and medical beauty sector has shown weaker performance compared to the market, with the Shenwan Beauty Care Index rising by 1.5% from July 4 to July 11, 2025, which is below the market average [3][5]. - The introduction of new products in the regenerative medicine sector, particularly in the "童颜针" (youthful needle) category, is expected to enhance consumer interest and expand the market [2][8]. - The report highlights strong anticipated earnings growth for several key companies in the cosmetics sector for the second quarter of 2025, with notable increases in revenue and net profit for brands like 上美股份 (Shangmei), 丸美股份 (Marubi), and 珀莱雅 (Proya) [9][10][11]. Summary by Sections Industry Performance - The cosmetics and medical beauty sector has underperformed the market, with specific indices showing varied performance, such as the Shenwan Cosmetics Index increasing by 2.6% [3][5]. - The report notes that the demand for cosmetics is recovering, with a 4.1% year-on-year increase in retail sales for the first five months of 2025 [19][20]. Company Performance - 上美股份 (Shangmei) is expected to see a revenue increase of 16% and a net profit increase of 25% in the first half of 2025 [10]. - 丸美股份 (Marubi) anticipates a 22% revenue growth and a 28% increase in net profit for the second quarter of 2025 [10]. - 珀莱雅 (Proya) is projected to achieve a 10% revenue growth and a 15% increase in net profit for the second quarter of 2025 [10]. - 毛戈平 (Mao Geping) expects a significant revenue increase of 38% and a net profit increase of 35% in the first half of 2025 [10]. - 若羽臣 (Ruoyuchen) forecasts a remarkable 70% revenue growth and a 75% increase in net profit for the second quarter of 2025 [10]. Market Trends - The report emphasizes the ongoing trend of domestic brands gaining market share, with national brands occupying five of the top ten positions in the skincare market [32]. - The regenerative medicine sector is expanding, with new products enhancing consumer engagement and market growth potential [2][8]. Investment Recommendations - The report recommends focusing on companies with strong brand matrices and high growth potential, such as 上美股份 (Shangmei), 珀莱雅 (Proya), and 丸美股份 (Marubi) [14]. - It suggests monitoring companies that leverage e-commerce and social media platforms effectively, such as 若羽臣 (Ruoyuchen) and 毛戈平 (Mao Geping) [14].

Summary of Key Points Core Viewpoint - JNRY VIII HK Holdings Limited, a major shareholder of Runben Biotechnology Co., Ltd., has completed a share reduction plan, selling a total of 3,608,400 shares, which is 0.89% of the company's total share capital [2][3][4]. Group 1: Shareholder Holding Situation - Before the reduction plan, JNRY VIII held 22,252,566 shares, accounting for 5.50% of the total share capital of the company [2]. Group 2: Reduction Plan Implementation Results - The reduction plan announced on March 19, 2025, allowed JNRY VIII to reduce up to 12,137,799 shares (3.00% of total share capital) through both centralized bidding and block trading [3]. - The actual reduction was completed within the specified timeframe, and the total shares reduced were consistent with the previously disclosed plan [4]. - The reduction included a maximum of 4,045,933 shares through centralized bidding (1.00% of total share capital) and 8,091,866 shares through block trading (2.00% of total share capital) [3].

Summary of Key Points Core Viewpoint - JNRY VIII HK Holdings Limited, a major shareholder of Runben Biotechnology Co., Ltd., has executed a share reduction plan, selling a total of 3,608,400 shares, which is 0.89% of the company's total share capital, as part of its investment strategy [1][2]. Group 1: Shareholder Information - JNRY VIII held 22,252,566 shares before the reduction, representing 5.50% of the total share capital [1]. - The shares were acquired prior to the company's IPO and became tradable on October 17, 2024 [1]. Group 2: Reduction Plan Implementation - The reduction plan allowed for a maximum sale of 12,137,799 shares (3.00% of total shares), with specific limits of 4,045,933 shares (1.00%) through open market transactions and 8,091,866 shares (2.00%) through block trades [1]. - The actual reduction was completed within the designated timeframe, with the shares sold at prices ranging from 30.01 to 36.20 yuan per share, totaling approximately 123.24 million yuan [2][3]. Group 3: Current Shareholding Status - After the reduction, JNRY VIII currently holds 18,644,166 shares, which is 4.61% of the total share capital [2]. - The reduction plan was executed as planned, with no early termination of the plan [3].

证券代码：603193 证券简称：润本股份 公告编号：2025-028 润本生物技术股份有限公司 股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 股东持股的基本情况 本次减持计划实施前，润本生物技术股份有限公司（以下简称"公司"）持股 5%以上 股东 JNRY VIII HK Holdings Limited（以下简称"JNRY VIII"）持有公司股份 22,252,566 股， 占公司总股本的 5.50%。上述股份来源为公司 IPO 前取得的股份，上述 IPO 前取得的股份 已于 2024 年 10 月 17 日解除限售并上市流通。 减持计划的实施结果情况 2025 年 3 月 19 日，公司披露了《关于持股 5%以上股东减持股份计划的公告》（公告编 号：2025-004），JNRY VIII 因基金投资运作需求，拟以集中竞价、大宗交易方式合计减持公 司股份不超过 12,137,799 股（即不超过公司总股本的 3.00%），其中：通过集中竞价交易方 式减持的，减持股份的总数 ...

Investment Rating - The report rates the cosmetics and medical beauty industry as "Positive" [2][3] Core Viewpoints - The cosmetics retail sales growth for January to May 2025 is 4.1%, an increase of 2 percentage points compared to the same period last year, indicating a steady recovery in demand [3] - The performance of leading brands remains strong, with double-digit growth, supported by the theme of self-care in new consumption trends, leading to a positive outlook for the first half of 2025 [3] - The 618 shopping festival saw strong performances from domestic brands, with notable rankings on platforms like Tmall and Douyin [3] Summary by Sections Cosmetics Industry Outlook - The report anticipates significant revenue and net profit growth for major companies in Q2 and H1 2025, with specific forecasts: - Up Beauty Co. is expected to see a revenue increase of 16% and a net profit increase of 25% [3] - Marubi is projected to grow revenue by 22% and net profit by 28% in Q2 2025 [3] - Proya is expected to achieve a revenue growth of 10% and net profit growth of 15% in Q2 2025 [3] Key Companies Performance - Notable companies and their expected performance include: - Mao Geping is projected to have a revenue increase of 38% and net profit increase of 35% in H1 2025 [3] - Ruibin is expected to see a revenue increase of 15% and net profit increase of 15% in Q2 2025 [3] - Huaxi Biological is expected to maintain stable performance with a 0% revenue growth and a 10% net profit increase in Q2 2025 [3] Investment Recommendations - The report recommends focusing on companies with strong brand matrices and comprehensive product layouts, such as Up Beauty Co., Marubi, and Proya, which are expected to benefit from the live e-commerce traffic [3] - It also highlights the importance of niche market players like Ruibin and Mao Geping, who are positioned to capitalize on the rise of personal care and domestic beauty trends [3] - For the medical beauty sector, the report suggests focusing on companies with high R&D barriers and strong profitability, recommending companies like Aimeike and Langzi [3] E-commerce and Other Segments - The report suggests monitoring e-commerce companies like Ruibin, which is expected to see significant growth in revenue and net profit [3] - In the maternal and infant sector, Kid King is projected to exceed market expectations with a revenue increase of 10% and a net profit increase of 70% in Q2 2025 [3]

Investment Rating - The report maintains an "Overweight" rating for the industry, with a focus on new consumption sectors such as beauty care, IP derivatives, and gold jewelry [5][29]. Core Insights - The report highlights significant market performance for the week of June 23-27, 2025, with retail, social services, and beauty care sectors increasing by 4.56%, 4.61%, and 1.04% respectively, outperforming the Shanghai Composite Index which rose by 1.91% [14][17]. - Key events include the strategic investment of 3.4 billion yuan by Jianbo Biological into Yangshengtang, and the successful IPO of Yingtong Holdings on the Hong Kong Stock Exchange [3][28]. Summary by Sections Market Performance - The retail, social services, and beauty care sectors ranked 9th, 8th, and 24th among 31 primary industries, with notable increases in sub-sectors such as education, professional chains, and trade, which rose by 7.47%, 7.42%, and 5.2% respectively [14][17]. Key Industry Data and News - In the beauty care sector, significant developments include the entry of Kefu Mei into Malaysia's Watsons, becoming the first Chinese efficacy skincare brand in the region, and the announcement by the National Medical Products Administration regarding the management of cosmetic raw materials [23][24]. - Jianbo Biological's restructuring of its collagen product to a medical device category and the successful listing of Yingtong Holdings are also noteworthy [3][24]. Investment Recommendations - The report recommends focusing on companies such as Shangmei Co., Ltd., Juzhi Biological, Marubi Biological, Runben Co., Ltd., Proya, Chaohongji, Blukoo, and Furuida as potential investment targets within the highlighted sectors [5][29].

Investment Rating - Industry rating: Recommended [5] Core Insights - The beauty sector experienced a stable conclusion during the 618 shopping festival, with significant changes in platform and brand dynamics driven by reduced commission policies and interest-based content ecosystems [1][2] - The total GMV for beauty products across four major e-commerce platforms (Taobao, JD, Douyin, Kuaishou) during the 618 period was between 600-700 billion yuan, reflecting a year-on-year growth of over 10% [1] - Taobao maintained the largest market share at 41.3%, followed by Douyin at 35.7%, JD at 14.8%, and Kuaishou at 8.2% [1][13] Summary by Sections E-commerce Platform Dynamics - Douyin's beauty segment is rapidly growing, supported by merchant subsidies and interest-driven consumer engagement, achieving double-digit growth [2] - Douyin's promotional strategies included a 1.4 billion yuan subsidy for merchants in May, with individual merchant reductions reaching up to 2.99 million yuan [2] Skincare and Makeup Categories - In the skincare category, domestic brands like Proya and Han Shu led the market, maintaining their top positions on Taobao and Douyin [3] - The top five brands in the skincare category on Taobao remained stable, with Proya and Han Shu continuing to dominate [3] - In the makeup and fragrance category, new domestic brands are emerging, with Ti Luo Wei achieving rapid growth by focusing on base makeup products [4] International and Domestic Brand Strategies - International brands are performing well due to localized marketing strategies and a willingness to engage with local consumers [8] - Domestic brands are expected to break out of the competitive cycle focused on ingredients and efficacy, emphasizing brand influence and comprehensive user experience [8] Investment Recommendations - Focus on domestic companies with strong brand equity and comprehensive channel strategies, particularly Proya and Han Shu [9] - Highlight technology-driven skincare brands like Betaini and Juzi Biology that target specific consumer needs [9] - Consider daily chemical brands with strong cost-performance ratios and excellent management of emerging channels, such as Runben and Dengkang [9]